Forty sandwich osteotomies in atrophic mandibles: a retrospective study.

Purpose: The aim of the present retrospective study was to assess the suitability of segmental mandibular sandwich osteotomy combined with an interpositional autograft to meet the dimensional requirements of preimplant bone augmentation in cases of a severely atrophic mandible.

Patients And Methods: A total of 27 consecutive patients (6 men and 21 women) were included in the present study. The amount of bone gain was calculated using digital volume tomography before surgery and 3 months after bone augmentation.

A preliminary report about treatment of bisphosphonate related osteonecrosis of the jaw with Er:YAG laser ablation.

Background And Objectives: This preliminary report describes a new laser-assisted treatment option for the emerging complication of bisphosphonate related osteonecrosis (BON) of the jaw.

Materials And Methods: In eight tumour patients (three women, five men) ten bony lesions in the maxilla and mandible in the course of intravenous bisphosphonate therapy were treated with a variable square pulsed (VSP) Er:YAG laser. For the treatment, the Er:YAG laser was applied with a pulse energy of 1,000 mJ, a pulse duration of 300 microseconds, and a frequency of 12 Hz (energy density 157 J/cm(2)).

Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.

The peroxisome proliferator-activated receptors (PPARs) represent pharmacological target molecules to improve insulin resistance in type 2 diabetes mellitus. Here we assessed a functional connection between pharmacological activation of PPAR and vascular endothelial growth factor (VEGF) expression in keratinocytes and during diabetes-impaired acute skin repair in obese/obese (ob/ob) mice. PPARbeta/delta agonist 4-[3-[4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid (L165,041) and PPARgamma agonists ciglitazone and troglitazone, but not rosiglitazone, potently induced VEGF mRNA and protein expression from cultured keratinocytes.

[First experiences in maxillary arch expansion using the MWD (Maxillary Widening Device)].

Aim: Conventional devices for surgical assisted rapid palatinal expansion are either tooth or bone borne. During clinical application over years, system dependant deficiencies, using either device became apparent. So together with Normed, Tuttlingen, we developed a new bone borne distractor (MWD, Maxillary Widening Device).